A Second View: Discussing LLY's Mounjaro (tirzepatide) as a weight loss treatment for patients with obesity and other overweight-related health problems

Executed on:Dec 5, 2022 11:00 AM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Mayo ClinicProfessor of Medicine & Consultant, Division of Endocrinology, Diabetes, Metabolism, Nutrition, Department of Internal Medicine at the Mayo Clinic.
Manages 40 patients monthly with obesity.
His lab studies the effects of obesity and how body fat (adipose tissue) and body fat distribution influence health; research involves measuring free fatty acid release in order to relate these factors to organ and tissue function with a goal of understanding the regulation of body fat and body fat distribution, in hopes of developing novel approaches to improve the health of humans affected by obesity or excess fat.

Interview Goal

This conversation will focus on a doctor's perspective managing patients with obesity and other overweight-related health problems. We will dig into the standard of care and the potential of Eli Lily's diabetes/weight loss drug, Mounjaro (tirzepatide).

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.